- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
- Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
- Cullinan Oncology to Participate in Upcoming Investor Conferences
- Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
- Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
More ▼
Key statistics
On Friday, Cullinan Therapeutics Inc (CGEM:NSQ) closed at 25.30, -1.61% below its 52-week high of 25.72, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.27 |
---|---|
High | 25.72 |
Low | 19.27 |
Bid | 25.06 |
Offer | 25.73 |
Previous close | 19.25 |
Average volume | 1.61m |
---|---|
Shares outstanding | 43.07m |
Free float | 40.31m |
P/E (TTM) | -- |
Market cap | 1.09bn USD |
EPS (TTM) | -3.70 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼